Loading organizations...
§ Private Profile · Bergen, Hordaland, Norway
Clinical-stage biotech develops synthetic peptide immunotherapies for oncology, targeting tumor cell membranes.
Cytovation is a clinical-stage biotechnology company based in Bergen, Norway, that develops synthetic peptide immunotherapies for oncology and rare diseases. The firm focuses on precision treatments that target tumor cell membranes and inhibit Wnt/β-catenin signaling, with its lead candidate, CyPep-1, currently advancing through Phase I/IIa clinical trials for conditions such as melanoma. Operating with a workforce of between 1 and 50 employees, the enterprise has raised a total of $34 million in venture capital funding, which includes an $18 million Series A financing round completed in 2021. The organization is backed by lead investors Sandwater and Canica, and it maintains strategic clinical collaborations with prominent industry entities including Merck and Cancer Research UK. Cytovation was officially founded in 2001 as a research spin-out from the University of Bergen by scientific founder and chief executive officer Lars Prestegarden.
Cytovation has raised $30.4M across 3 funding rounds.
Cytovation has raised $30.4M in total across 3 funding rounds.
Cytovation has raised $30.4M across 3 funding rounds. Most recently, it raised $8.0M Series A Extension in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 2, 2023 | $8M Series A Plus | Canica, Sandwater | — | Announced |
| Jan 25, 2022 | $20M Series A | Christer Kjos, Morten E. Iversen | — | Announced |
| Jun 29, 2017 | $2.4M Venture Round | — | — | Announced |
Cytovation has raised $30.4M in total across 3 funding rounds.
Cytovation's investors include Canica, Sandwater, Christer Kjos, Morten E. Iversen.